Importance of Formulation for the Success of Biotherapeutics
Tudor Arvinte, Chairman and CEO, Therapeomics Inc/University of Geneva, Switzerland

The talk will present case studies documenting the importance of formulation for the proof-of-concept of new biopharmaceutics as well as for the success of clinical trials and market launch. 

Bicyclic Peptides with Antibody-Like Binding Affinity and Specificity
Vanessa Baeriswyl, Postdoc Researcher, EPFL, Switzerland

We are generating bicyclic peptide ligands for disease targets using an approach based on phage display technology. The bicyclic peptides combine key qualities of antibody therapeutics (high affinity and specificity) and advantages of small molecule drugs.

Immunogenicity Assessment for the Successful Development of Biosimilars
Michael Tovey, Director, Institut Andre Lwoff/INSERM, France

Successful development of biosimilars requires the establishment of a validated and standardized assay that allows direct comparisons of the relative potency and immunogenicity of innovator molecules and biosimilars as illustrated by case studies for interferon beta products and TNF-alpha antagonists.

Regulation of antibody immunotherapy by fine-tuning FcR interactions
, , SelectBio, United Kingdom